289 studies found for:    Exclude Unknown | Expanded Access Studies
Show Display Options
Download search resultsDownload the search results for:
Exclude Unknown | Expanded Access Studies (289 records)
Download Content:
Zip file readers with free trial periods: WinZip or PKZip
Rank Status Study
1 Available Study of the Use of [18F]-DOPA in Hyperinsulinemic Hypoglycemia
Conditions: Hyperinsulinemic Hypoglycemia, Persistent;   Congenital Hyperinsulinism;   Persistent Hyperinsulinemic Hypoglycemia of Infancy (PHHI)
Intervention: Drug: 18 F-DOPA
2 Available EAP of CPX-351 for Patients 60-75 Years of Age With Secondary AML
Condition: Secondary AML
Intervention: Drug: CPX-351
3 Available Detecting Recurrent Prostate Cancer With 11C-choline Positron Emission Tomography
Conditions: Prostate Cancer;   Recurrent Prostate Cancer
Interventions: Drug: 11C-choline;   Device: PET/CT Scan
4 Temporarily not available Emergent Expanded Access for ahSC Augmentation of Nerve Autografts After Severe Peripheral Nerve Injury.
Condition: Sciatic Nerve Injury
Intervention: Biological: Autologous human Schwann cells
5 Available Triheptanoin (UX007) to Treat Citrate Transporter Deficiency
Conditions: Citrate Transporter Deficiency;   SLC13A5 Gene Mutation
Intervention: Drug: triheptanoin
6 Available Expanded Access Program for Asfotase Alfa Treatment for Patients With Infantile- or Juvenile-onset Hypophosphatasia (HPP)
Condition: Hypophosphatasia
Intervention: Biological: asfotase alfa
7 Available Domperidone Expanded Access Program for Oncology Patients With Gastroparesis Who Have Failed Standard Therapy
Condition: Oncology Patients With Gastroparesis
Intervention: Drug: Oral Domperidone
8 No longer available Expanded Access for Single Patient Treatment of Autologous Human Schwann Cells (ahSC) for Peripheral Nerve Repair
Condition: Sciatic Nerve Injury
Intervention: Biological: Autologous Human Schwann cells
9 Available Early Access Treatment With Daratumumab for (Relapsed or Refractory) Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: Daratumumab
10 Available Expanded Access Program With Nivolumab Monotherapy for Treatment of Advanced/Metastatic SqNSCLC After One Prior Systemic Regimen
Condition: Non-Small Cell Lung Cancer
Intervention: Drug: Nivolumab
11 Temporarily not available Safety and Efficacy of Autologous Concentrated Bone Marrow Aspirate for Critical Limb Ischemia - Continued Access
Conditions: Peripheral Arterial Disease;   Peripheral Vascular Diseases;   Critical Limb Ischemia
Intervention: Device: Bone marrow concentration device
12 Available Pilot Trial of HER-2/Neu Pulsed DC1 Vaccine for Patients With HER-2 Positive Metastatic Cancer
Condition: Metastatic Cancer
Intervention: Biological: HER-2/neu Pulsed DC1 vaccine
13 Temporarily not available Crizotinib (Xalkori) Expanded Access Protocol For The Treatment Of Adult Or Pediatric Patients
Condition: Neoplasm
Intervention: Drug: Crizotinib
14 Available Treatment of Drug Resistant Epilepsy
Condition: Epilepsy
Interventions: Drug: Epidiolex®;   Other: Blood Test
15 Available AZD9291 US Expanded Access Program
Condition: EGFR T790M Mutation Positive NSCLC
Intervention: Drug: AZD9291
16 Available Early Access Program (EAP) for Ibrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Condition: B-cell Chronic Lymphocytic Leukemia
Intervention: Drug: PCI-32765 (Ibrutinib)
17 Temporarily not available HAIC Using Oxaliplatin Plus Fluorouracil/Leucovorin for Patients With Locally Advanced HCC
Conditions: Hepatocellular Carcinoma;   Injury; Blood Vessel, Hepatic, Artery
Interventions: Procedure: HAIC using oxaliplatin plus fluorouracil/leucovorin;   Drug: Oxaliplatin;   Drug: Fluorouracil;   Drug: Leucovorin
18 Available HUD: PIP Joint Implant
Conditions: Arthrosis;   Osteoarthrosis
Intervention: Device: SR PIP Implant System
19 Available An Open Label, Expanded Access Protocol With SAGE-547 for Super-Refractory Status Epilepticus
Condition: Super-Refractory Status Epilepticus
Intervention: Drug: SAGE-547
20 Available [18 F]-6-L-fluorodihydroxyphenylalanine (18F-FDOPA) Positron Emission Tomography (PET) in Neuroendocrine Tumours
Conditions: Thyroid Cancer, Medullary;   Carcinoid Tumor;   Pheochromocytoma;   Paraganglioma;   Insulinoma;   Neuroblastoma
Intervention: Drug: [18 F]-6-L-fluorodihydroxyphenylalanine (18F-FDOPA)

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years